Postmenopausal Osteoporosis Treatment Market Size - By Drug Type (Bisphosphonates, Hormone Replacement Therapy (HRT)), Route of Administration, Distribution Channel, Global Forecast (2023-2032)
Postmenopausal Osteoporosis Treatment Market Size - By Drug Type (Bisphosphonates, Hormone Replacement Therapy (HRT)), Route of Administration, Distribution Channel, Global Forecast (2023-2032)
Postmenopausal Osteoporosis Treatment Market size is estimated to depict 4.6% CAGR from 2023 to 2032 attributed to the surge in supportive government initiatives and healthcare policies worldwide. The influx of subsidized healthcare services, medication affordability, and supportive R&D initiatives are creating an environment conducive to effective osteoporosis management. Additionally, there has been significant increase in government-driven regulations and guidelines for ensuring quality standards and patient safety while promoting the integration of innovative treatment approaches.
Furthermore, the rising efforts by industry players on strengthening their market position through the development of advanced generic formulations and device engineering to enhance patient access to crucial treatment options will augment the industry outlook. For instance, in November 2023, Teva Pharmaceuticals Inc., a U.S. subsidiary of Teva Pharmaceutical Industries Ltd. received approval to market the generic version of Forteo®1, an injectable containing teriparatide, prescribed to treat osteoporosis in certain male and female patients.
The postmenopausal osteoporosis treatment industry is segmented into drug type, route of administration, distribution channel, and region.
Based on drug type, the market share from the hormone replacement therapy (HRT) segment is anticipated to gain 4.8% CAGR between 2023 and 2032. HRT has emerged as an effective treatment approach for postmenopausal osteoporosis as it helps to maintain bone density, reduce fracture risk, and manage symptoms. Additionally, the increasing adoption of hormone replacement therapies to treat postmenopausal women coupled with the ongoing R&D efforts for formulations will propel the segment expansion.
In terms of distribution channel, the postmenopausal osteoporosis treatment industry from the hospital pharmacies segment is estimated to record 3.7% growth rate through 2032. Hospital pharmacies serve as crucial distribution points for osteoporosis medications for ensuring accessibility to prescribed treatments. The convenience of obtaining medications from hospital pharmacies and the higher availability of expert healthcare professionals at hospitals will contribute to the segment growth.
Regionally, the Asia Pacific postmenopausal osteoporosis treatment market is set to exhibit 5.2% growth rate through 2032 driven by the aging population and increasing awareness of osteoporosis management. According to NCBI estimations published in 2023, Asia will account for more than half of all fractures caused by osteoporosis by 2050, with postmenopausal women being the most vulnerable. This rising prevalence of osteoporosis among postmenopausal women across the region is expected to fuel the demand for advanced therapies. Moreover, the rising healthcare expenditure, improving healthcare infrastructure, and government initiatives will further boost the adoption of postmenopausal osteoporosis treatments in the region.